Technology

Aclaris Therapeutics

$18.02
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.86 (-4.57%) Today
+$0.05 (+0.28%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ACRS and other stocks, options, and ETFs commission-free!

About ACRS

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA. The listed name for ACRS is Aclaris Therapeutics, Inc. Common Stock.

CEO
Neal S. Walker
Employees
77
Headquarters
Malvern, Pennsylvania
Founded
2012
Market Cap
771.26M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
11.84M
High Today
$24.27
Low Today
$17.71
Open Price
$19.98
Volume
20.42M
52 Week High
$24.27
52 Week Low
$0.70

Collections

ACRS News

MarketWatchJan 19

Aclaris Therapeutics stock more than triples after 'positive' data on arthritis treatment trial

Shares of Aclaris Therapeutics Inc. ACRS, +208.42% skyrocketed more than 200% toward a 2 1/2-year high, on massive volume, in midday trading Tuesday, after the

ACRS Earnings

-$1.24
-$0.83
-$0.41
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market

You May Also Like

ANAB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure